Skip to content
DataLookout
Menu

ROXI-CAT-INCT07410117

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 23 → 28 locations
  2. Minor Trial sites expanded: 20 → 23 locations
  3. Minor Study sites revised (20)
  4. Notable Eligibility criteria expanded, about 8 words
    • Trial sites expanded: 14 → 20 locations
  5. Minor Study sites: 13 to 14v6
  6. Minor Study sites: 12 to 13v5
  7. Notable Primary endpoint(s) modified
    • Eligibility criteria shortened, about 6 words
    • Enrollment increased: 860 → 1120 participants
    • Secondary endpoints: 8 to 16
    v4
  8. Minor Trial sites expanded: 5 → 12 locationsv3
  9. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Jul 21, 2029 to Jan 23, 2030
    • Study sites: 0 to 5
    • Study completion date: Nov 1, 2029 to May 6, 2030
    • Start date changed from estimate of Feb 16, 2026 to Mar 9, 2026
  10. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Time-to-first event of centrally adjudicated VTE (DVT, PE) or ATE, or thromboembolism- or ATE-related death
Timeframe: Through 6 months
Time-to-first event of centrally adjudicated International Society of Thrombosis and Hemostasis (ISTH) major bleeding or Clinically Relevant Non-Major (CRNM) bleeding
Timeframe: Through 6 months

Secondary (16)

Time-to-first event of the centrally adjudicated symptomatic or incidental VTE (DVT, PE) or ATE and thromboembolism- or ATE-related death
Time-to-first event of symptomatic VTE
Time-to-first event of symptomatic DVT
Time-to-first event of symptomatic non-fatal PE
Time-to-first event of thromboembolism-related death
Show 11 moreShow less
Time-to-first event of incidental VTE
Time-to-first event of incidental upper extremity or incidental proximal lower extremity DVT
Time-to-first event of incidental non-fatal PE (in a segmental or larger pulmonary artery)
Time-to-first event of asymptomatic VTE (Asymptomatic DVT detected by lower extremities ultrasound)
Time-to-first event of ATE
Time-to-first event of ATE-related death
Time-to-first event of centrally adjudicated VTE (DVT, PE), or thromboembolism-related death
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Severity of TEAEs
Occurrence of Anti-Drug Antibody (ADA) to REGN7508
Magnitude of ADA to REGN7508

Arms and interventions

REGN7508Experimental
PlaceboPlacebo comparator

Drugs: REGN7508, Placebo

Sites

28 sites in 3 countries

Japan 13, Georgia 10, United States 5